Coya Therapeutics stock maintains Buy rating at H.C. Wainwright on ALS trial launch

Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ:COYA), representing a significant upside from the current price of $5.47, following the company’s announcement of its ALSTARS Trial launch. According to InvestingPro data, analyst targets range from $14 to $20, with a strong buy consensus.

The Phase 2 clinical trial will evaluate COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, multi-center, double-blind, placebo-controlled study aims to enroll 120 patients across approximately 25 clinical sites in the U.S. and Canada. The $91.49M market cap company maintains a strong financial position, with InvestingPro analysis showing a healthy current ratio of 7.43 and more cash than debt on its balance sheet (Discover 8 more key financial insights with InvestingPro).

Study participants will be randomized to receive one of two different doses of COYA 302 or placebo during the initial 24-week, double-blinded phase. Those completing this phase will be invited to join a 24-week blinded extension to assess long-term safety and efficacy, during which all participants will receive COYA 302 at one of two pre-specified doses.

The company plans to add more clinical locations as the trial progresses. Details of the study will be presented on September 29, 2025, during the NEALS Educational Webinar by Dr. James Berry, M.D., M.P.H.

H.C. Wainwright analyst Raghuram Selvaraju maintained the firm’s 12-month price target of $18 on Coya Therapeutics stock following this development.

In other recent news, Coya Therapeutics has made significant strides in its development efforts for ALS treatment. The company announced the initiation of its Phase 2 ALSTARS trial, a randomized, multi-center study to assess the safety and effectiveness of COYA 302 in ALS patients. This follows the U.S. Food and Drug Administration’s acceptance of Coya’s Investigational New Drug (IND) application for COYA 302, which triggered a $4.2 million milestone payment from its partner, Dr. Reddy’s Laboratories Ltd.

Analyst firms have shown confidence in Coya’s potential, with Lucid Capital Markets, H.C. Wainwright, BTIG, and Lake Street Capital all reiterating Buy ratings on the stock. Lucid Capital Markets maintains a price target of $20.00, while H.C. Wainwright and BTIG have set targets of $18.00 and $15.00, respectively. Lake Street Capital initiated coverage with a Buy rating and a $16.00 price target, citing the upside potential of Coya’s COYA-302 treatment. These developments are underscored by positive clinical data for COYA-302 in ALS and frontotemporal dementia patients. The acceptance of the IND application by the FDA is seen as a crucial step toward initiating a potentially registrational Phase 2/3 study.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.